Pharma in Focus - knowledge in power
6 - 12 Sep 2010
 
Drug Tracker: CE rejection rate problematic for pricing
The latest Drug Tracker analysis of PBAC outcomes shows that an increasing rejection rate for major cost-effectiveness submissions may have potential to affect return on investment for new drugs and indications
Roche reacts to changing pharma environment
Roche has wasted no time in reacting to a series of delays and disappointments that have affected its business over recent months and to changing pressures in the world of drug funding
Subscribe to Pharma in Focus

Sign Up Now

What you'll pay

A two week trial of Pharma in Focus is FREE of charge.

Paid subscription to Pharma in Focus costs $359.95 per year.

Special rates for groups of five or more are also available.
For further information, contact our sales department on 02 9972 0125

3 Simple Steps

Fill in your details below and submit
Make your subscription choice
Make your payment choice (Credit Card, Direct Deposit or Cheque)

Email Address
Retype your Email Address
First Name
Last name
Company or Organisation
Position
Phone
Prove you are human
 
Send me News Alerts as
HTML (colourful) OR Text only
 

Note: When your subscription has expired we hope you will renew it but we will continue to send you the daily Pharma in Focus News Alert whether you renew or not. You can unsubscribe from this service at any time.

Access: Full text access is immediate upon email verification.

Privacy policy: The list on which your email address appears is protected and will not be sold or passed on to any other organisation or individual.

TOP | BACK

 

 
Instant Update - Tues 6 Sept
..full report
Roche reviews global job numbers
..full report
Sigma slapped with class action
..full report
Common code considered likely
..full report
Abbott's Reductil patent upheld
..full report
PBS processes given IT overhaul
..full report
Arimidex competitors line up
..full report
Codeine combos still a problem
..full report

© 2007 Lush Media | Privacy Statement | Subscribe to Pharma in Focus